For Immediate Release: May 30, 2018
513-579-9911 x 12627
Medpace Receives Six CRO Leadership Awards
Primary market research report recognizes Medpace for excellence in
Capabilities, Compatibility, Expertise, Quality, Reliability and Phase IV
CINCINNATI, OH — (May 30, 2018) – Medpace (MEDP), a scientifically-driven, global full-service clinical research organization (CRO), has been recognized with six CRO Leadership Awards from Life Science Leader magazine in all award categories. The awards are based on research from Industry Standard Research’s (ISRs) Contract Research Organization Quality Benchmarking annual online survey in which 70 contract research organizations were assessed on 20+ performance metrics.
Medpace has won a 2018 CRO Leadership Award in the following categories:
- Capabilities (Overall, Big Pharma, Small Pharma)
- Compatibility (Overall, Big Pharma Small Pharma)
- Expertise (Overall, Big Pharma, Small Pharma)
- Quality (Overall, Big Pharma, Small Pharma)
- Reliability (Overall, Big Pharma, Small Pharma)
- Phase IV (Overall)
“Life Science Leader is proud to be working with ISR Reports to honor those CROs that have proven themselves to be the top performers in Compatibility, Capabilities, Expertise, Quality, Reliability, and Phase IV,” said Ed Miseta, Executive Editor, Life Science Leader. “The winners were decided by looking at 20+ different performance metrics, as rated by decision-making executives at biopharmaceutical companies. The CROs receiving an award this year are truly at the top of their class, and are deserving of the recognition they receive. Being a top performer in any of these categories shows a level of expertise and commitment to clinical trials and serving the needs of biopharmaceutical companies and their patients.”
Medpace will be presented with its CRO Leadership Awards at this year’s DIA Annual Meeting in Boston on June 25.
“Medpace is honored to receive this recognition—especially across so many categories,” commented Jesse Geiger, Chief Operating Officer. “This award is a reflection of our talented people, their dedication to our mission, and a depth of expertise that allows us to carry out complex and scientifically challenging programs. We pride ourselves on our full-service, therapeutically-focused, and scientifically-driven model, which provides the framework that enables us to truly partner with our clients and accelerate their clinical development.”
Medpace also received first place in the ACRP-Avoca CRO Quality Awards earlier this year.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,600 people across 36 countries.